Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

Study to determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI). 2011 October 12.

[button]Download[/button]

More Resources

09/18/2026

What a Head CT Can and Can’t Tell You About a Concussion

For Concussion Awareness Day, learn how quantitative CT analysis can help measure subtle structural changes and support follow-up after traumatic brain injury.

09/09/2026

Prostate Cancer Awareness Month: Finding the Cancer That Matters

How quantitative MRI can bring greater clarity to decisions across the prostate cancer journey.

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation
Scroll to Top